November 27, 2018, MedPage Today 

Clinicians should offer pre-exposure prophylaxis (PrEP) with antiretroviral therapy to patients at high risk for HIV infection, the U.S. Preventive Services Task Force (USPSTF) said. For the first time, the USPSTF reviewed the topic and determined that, when taken as prescribed, PrEP is highly effective at preventing HIV among those at high risk, and concluded with "high certainty" that there is a "substantial benefit" to use in this population ("A" recommendation). 

Read more.